**Acute Myeloid Leukemia – Relapsed/Refractory**

- **No specific mutation/target**

**IRB# 18238:**
Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia

**IRB# 18253:**
A Phase 1, Open-Label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies

**IRB# 17577:**
Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumour Activity of Ascending Doses of AZD5991 Monotherapy and in Combination with Venetoclax in Subjects with Relapsed or Refractory Haematologic Malignancies

**IRB # 22070**
A Phase 1 Study TAS1440, as a Single Agent and in Combination with All-Trans Retinoic Acid (ATRA) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML)

**IRB # 22757**
IRB# 18253
Phase 1/1b/2a, 3-Part, Open-Label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies

**IRB # 21970**
A Phase 1 Study of Intravenously Administered ID-202 and ID-202 Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) Patients

**IRB # 24160**
A Randomized, Open-Label Study of the Efficacy and Safety of Galapagosmum S (GPS) Maintenance Monotherapy Compared to Investigator’s Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

**IRB # 24165**
Phase I, Open-Label, Dose-escalation Study of SNDX-5613 in Combination with Chemotherapy in R/R Leukemias

**IRB # 24205**
A Phase I Study of Entrectinib in Combination with venetoclax plus azacitidine

**IRB # 24205**
A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 positive Acute Leukemia and T Cell Lymphoblastic Lymphoma

**IRB # 24205**
A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 positive Acute Leukemia and T Cell Lymphoblastic Lymphoma

**IRB # 24205**
A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 positive Acute Leukemia and T Cell Lymphoblastic Lymphoma

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

**Genetic mutation/target**
- TP53
- CD38
- FLT3
- NPM1
- MLL/MLLT2A or NPM1